Johannes Gerardus Chri Schikan Sells 200,000 Shares of Pharvaris (NASDAQ:PHVS) Stock

Pharvaris N.V. (NASDAQ:PHVS) Director Johannes Gerardus Chri Schikan sold 200,000 shares of Pharvaris stock in a transaction on Thursday, September 17th. The stock was sold at an average price of $35.00, for a total transaction of $7,000,000.00. Following the completion of the transaction, the director directly owned 115,167 shares in the company, valued at approximately $4,030,845. The trade was a 63.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Johannes Gerardus Chri Schikan also recently made the following trade(s):

• On Tuesday, June 30th, Johannes Gerardus Chri Schikan sold 30,712 shares of Pharvaris stock. The stock was sold at an average price of $35.49, for a total value of $1,089,968.88.
• On Monday, June 29th, Johannes Gerardus Chri Schikan sold 6,888 shares of Pharvaris stock. The stock was sold at an average price of $35.05, for a total value of $241,424.40.

Pharvaris Price Performance

Pharvaris stock traded down $0.35 during midday trading on Monday, reaching $36.02. The company’s stock had a trading volume of 653,689 shares, compared to its average volume of 412,750. Pharvaris N.V. has a 52-week low of $20.65 and a 52-week high of $43.25. The stock’s 50-day simple moving average is $35.37 and its 200-day simple moving average is $31.75. The stock has a market capitalization of $2.36 billion, a P/E ratio of -11.81 and a beta of -2.33.

Pharvaris (NASDAQ:PHVS) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.06). As a group, equities research analysts expect that Pharvaris N.V. will post -3.12 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. venBio Partners LLC acquired a new position in Pharvaris in the second quarter worth $160,569,809. 5AM Venture Management LLC bought a new position in Pharvaris in the 2nd quarter worth approximately $27,581,008. BlackRock Inc. acquired a new stake in Pharvaris during the second quarter valued at approximately $26,677,000. Elmind Capital LP bought a new stake in shares of Pharvaris during the second quarter valued at approximately $18,180,435. Finally, Seven Fleet Capital Management LP raised its position in shares of Pharvaris by 144.6% in the 2nd quarter. Seven Fleet Capital Management LP now owns 774,501 shares of the company’s stock valued at $26,782,000 after acquiring an additional 457,804 shares during the period.

Wall Street Analyst Weigh In

Several research firms have commented on PHVS. Citigroup reissued a “market outperform” rating on shares of Pharvaris in a research report on Wednesday, September 9th. HC Wainwright reissued a “buy” rating and issued a $60.00 price objective on shares of Pharvaris in a research report on Tuesday, September 8th. Guggenheim boosted their price target on Pharvaris from $40.00 to $44.00 and gave the stock a “buy” rating in a report on Thursday, September 10th. UBS Group set a $79.00 price target on shares of Pharvaris in a research note on Wednesday, September 9th. Finally, Morgan Stanley increased their price objective on Pharvaris from $46.00 to $62.00 and gave the company an “overweight” rating in a report on Wednesday, September 9th. Thirteen analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $59.87.

About Pharvaris

Pharvaris N.V. is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling. The company is headquartered in Zug, Switzerland, and was founded in 2015 by former executives from Pharming Group.

Pharvaris’ lead investigational medicine is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist. The company is evaluating different formulations of deucrictibant for both on-demand treatment of HAE attacks and long-term prevention of attacks.